-
公开(公告)号：US20110244033A1
公开(公告)日：2011-10-06
申请号：US13133877
申请日：2008-12-09
IPC分类号： A61K9/48 , A61K31/18 , A61K31/473 , A61P13/08 , A61P9/00
CPC分类号： A61K9/1652 , A61K9/1635 , A61K9/5026
摘要： The invention relates to a population of tamsulosin-comprising pellets for oral administration of a combination dosage form containing physically separated a tamsulosin dose in the form of the population of the tamsulosin comprising pellets and at least one other dose of a pharmaceutically active substance, said pellets comprising tamsulosin hydrochloride uniformly dispersed in a carrier matrix, wherein (i) said pellets in the population have a size of less than about 1.4 mm and, advantageously, at least 90% of the pellets have a size of larger than 0.30 mm; and (ii) an average content of tamsulosin hydrochloride in the population of pellets is between about 0.15-3.00 weight percent, calculated on a dry pellet basis, to a process of making such population of pellets, and to their use.
摘要翻译： 本发明涉及一种含有坦索罗辛的颗粒，用于口服给药组合剂型，其中包含以包含丸粒和至少一种其它剂量的药物活性物质的坦索罗辛群体的形式物理分离的坦索罗辛剂量，所述颗粒 其包含均匀分散在载体基质中的盐酸坦洛新，其中（i）群体中的所述粒料具有小于约1.4mm的尺寸，并且有利地，至少90％的粒料具有大于0.30mm的尺寸; 和（ii）颗粒群体中盐酸坦洛新的平均含量为基于干颗粒计算的约0.15-3.00重量％与制备这种颗粒群体的方法及其用途。
-
2.发明申请公开(公告)号：US20080317848A2
公开(公告)日：2008-12-25
申请号：US10492270
申请日：2004-04-08
申请人： Thomas Gramatte , Peter Gruber , Michael Heschel , Dirk Pamperin , Jan Ploen , Steffen Scheithauer , Wolfgang Wehner , Peter Guldner
发明人： Thomas Gramatte , Peter Gruber , Michael Heschel , Dirk Pamperin , Jan Ploen , Steffen Scheithauer , Wolfgang Wehner , Peter Guldner
IPC分类号： A61K31/445 , A61K9/20
CPC分类号： A61K9/2009 , A61K9/2054 , A61K9/2846 , A61K9/5026 , A61K9/5078 , A61K31/445
摘要： By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pKa value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.
摘要翻译： 通过合适的阻滞剂，可以制备含有丙哌嗪或其一种或多种药学上可接受的盐的药物组合物，其量为4mg至60mg propiverine并且具有延长的活性剂释放。 优选地，具有pKa值小于6.65的活性剂和任选的一种或多种酸性物质的混合物具有延迟涂层或嵌入基质中，然后任选地涂覆有进一步的阻滞层。
-
公开(公告)号：US20090017113A1
公开(公告)日：2009-01-15
申请号：US12171703
申请日：2008-07-11
申请人： Niels J. Osinga , Dirk Pamperin
发明人： Niels J. Osinga , Dirk Pamperin
CPC分类号： A61K9/5078 , A61K9/5026
摘要： Duloxetine pellets having an enteric coating containing a polymethacrylate polymer can be formed with desirable release rates/profile and stability.
摘要翻译： 具有包含聚甲基丙烯酸酯聚合物的肠溶衣的度洛西汀颗粒可以形成具有所需的释放速率/分布和稳定性。
-
公开(公告)号：US08465770B2
公开(公告)日：2013-06-18
申请号：US12634890
申请日：2009-12-10
IPC分类号： A61K9/24
CPC分类号： A61K31/18 , A61K9/2027 , A61K9/2054 , A61K9/2086
摘要： Low dose pharmaceuticals can be delivered for a prolonged period using a tablet-in-tablet design wherein the drug is contained in a controlled release matrix in the outer compression coating layer but not in the inner tablet core.
摘要翻译： 低剂量药物可以使用片剂式设计长时间递送，其中药物包含在外压缩涂层中的控释基质中，但不包含在内片芯中。
-
5.发明授权Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient 有权丙泊酚或其药学上可接受的盐的延长释放活性成分的口服剂型公开(公告)号：US07943176B2
公开(公告)日：2011-05-17
申请号：US10492270
申请日：2002-10-08
申请人： Thomas Gramatte , Peter Gruber , Michael Heschel , Dirk Pamperin , Jan Ploen , Steffen Scheithauser , Wolfgang Wehner , Peter Guldner
发明人： Thomas Gramatte , Peter Gruber , Michael Heschel , Dirk Pamperin , Jan Ploen , Steffen Scheithauser , Wolfgang Wehner , Peter Guldner
IPC分类号： A61K9/14
CPC分类号： A61K9/2009 , A61K9/2054 , A61K9/2846 , A61K9/5026 , A61K9/5078 , A61K31/445
摘要： By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pKa value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.
摘要翻译： 通过合适的阻滞剂，可以制备含有丙哌嗪或其一种或多种药学上可接受的盐的药物组合物，其量为4mg至60mg propiverine并且具有延长的活性剂释放。 优选地，具有pKa值小于6.65的活性剂和任选的一种或多种酸性物质的混合物具有延迟涂层或嵌入基质中，然后任选地涂覆有进一步的阻滞层。
-
公开(公告)号：US20100092552A1
公开(公告)日：2010-04-15
申请号：US12634890
申请日：2009-12-10
CPC分类号： A61K31/18 , A61K9/2027 , A61K9/2054 , A61K9/2086
摘要： Low dose pharmaceuticals can be delivered for a prolonged period using a tablet-in-tablet design wherein the drug is contained in a controlled release matrix in the outer compression coating layer but not in the inner tablet core.
摘要翻译： 低剂量药物可以使用片剂式设计长时间递送，其中药物包含在外压缩涂层中的控释基质中，但不包含在内片芯中。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.036 秒)
